Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Brigida Anna Maiorano; Martina Catalano; Evaristo Maiello; Giandomenico Roviello

doi:10.3389/fonc.2023.1254906

Frontiers in Oncology (Sep 2023)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Brigida Anna Maiorano,
Martina Catalano,
Evaristo Maiello,
Giandomenico Roviello

Affiliations

Brigida Anna Maiorano: Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Martina Catalano: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
Evaristo Maiello: Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Giandomenico Roviello: Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy

DOI: https://doi.org/10.3389/fonc.2023.1254906
Journal volume & issue: Vol. 13

Abstract

Read online

Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords